
Deerfield Doubles Down on Vera Therapeutics as Kidney Drug Nears FDA Decision
Deerfield Management increases Vera Therapeutics stake to $205.58M as kidney drug atacicept approaches July 7 FDA decision. Stock up 50% annually.
VERAFDA approvalbiotech


Investing.com··Jesse Cohen











Investing.com··Sam Quirke
